Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDCO Medicines	$84.90	$84.90	$17.81 ▼ $84.98	$6.77B	1.1	9.55 million shs	N/A
PFE Pfizer	$24.86 +1.3%	$24.83	$20.92 ▼ $30.43	$139.52B	0.55	34.76 million shs	34.59 million shs
SAN Banco Santander	$9.53 -0.6%	$8.97	$4.43 ▼ $9.82	$142.60B	1.08	3.35 million shs	3.06 million shs
SNY Sanofi	$46.50 +2.6%	$48.84	$44.73 ▼ $60.12	$111.31B	0.51	2.35 million shs	7.26 million shs
SNYNF Sanofi	$92.30 +0.5%	$97.24	$90.05 ▼ $122.03	N/A	N/A	40,049 shs	301,488 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDCO Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer	-1.01%	-0.39%	-0.75%	+4.90%	-13.65%
SAN Banco Santander	+1.61%	-0.70%	+10.18%	+19.37%	+99.31%
SNY Sanofi	-9.14%	-9.23%	-5.25%	-10.18%	-22.55%
SNYNF Sanofi	-7.90%	-7.63%	-1.06%	-10.86%	-21.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDCO Medicines	$84.90	$84.90	$17.81 ▼ $84.98	$6.77B	1.1	9.55 million shs	N/A
PFE Pfizer	$24.86 +1.3%	$24.83	$20.92 ▼ $30.43	$139.52B	0.55	34.76 million shs	34.59 million shs
SAN Banco Santander	$9.53 -0.6%	$8.97	$4.43 ▼ $9.82	$142.60B	1.08	3.35 million shs	3.06 million shs
SNY Sanofi	$46.50 +2.6%	$48.84	$44.73 ▼ $60.12	$111.31B	0.51	2.35 million shs	7.26 million shs
SNYNF Sanofi	$92.30 +0.5%	$97.24	$90.05 ▼ $122.03	N/A	N/A	40,049 shs	301,488 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDCO Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer	-1.01%	-0.39%	-0.75%	+4.90%	-13.65%
SAN Banco Santander	+1.61%	-0.70%	+10.18%	+19.37%	+99.31%
SNY Sanofi	-9.14%	-9.23%	-5.25%	-10.18%	-22.55%
SNYNF Sanofi	-7.90%	-7.63%	-1.06%	-10.86%	-21.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDCO Medicines	0.00	N/A	N/A	N/A
PFE Pfizer	2.39	Hold	$28.12	13.13% Upside
SAN Banco Santander	2.50	Moderate Buy	N/A	N/A
SNY Sanofi	3.22	Buy	$62.00	33.33% Upside
SNYNF Sanofi	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PFE, SNY, SNYNF, SAN, and MDCO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	SNY Sanofi	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
8/8/2025	SNY Sanofi	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$27.00 ➝ $28.00
8/5/2025	SNY Sanofi	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
8/1/2025	SAN Banco Santander	Kepler Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/2/2025	SNY Sanofi	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDCO Medicines	$6.14M	1,102.36	N/A	N/A	($0.30) per share	-283.00
PFE Pfizer	$63.63B	2.22	$4.42 per share	5.62	$15.62 per share	1.59
SAN Banco Santander	$66.96B	2.12	$1.08 per share	8.83	$7.34 per share	1.30
SNY Sanofi	$44.46B	2.57	$5.46 per share	8.51	$33.20 per share	1.40
SNYNF Sanofi	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDCO Medicines	-$123.16M	-$2.91	N/A	N/A	N/A	N/A	N/A	-25.70%	N/A
PFE Pfizer	$8.03B	$1.88	13.22	8.20	0.87	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
SAN Banco Santander	$13.61B	$0.90	10.58	10.35	1.07	17.30%	11.98%	0.71%	11/4/2025 (Estimated)
SNY Sanofi	$6.02B	$4.16	11.03	9.79	1.08	21.47%	16.86%	9.63%	10/24/2025 (Estimated)
SNYNF Sanofi	N/A	$3.08	29.92	∞	N/A	N/A	N/A	N/A	10/24/2025 (Estimated)

Latest PFE, SNY, SNYNF, SAN, and MDCO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/31/2025	Q2 2025	SNY Sanofi	$0.96	$0.90	-$0.06	$1.84	$9.91 billion	$11.34 billion
7/30/2025	Q2 2025	SAN Banco Santander	$0.26	$0.22	-$0.04	$0.25	$17.69 billion	$17.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDCO Medicines	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.92%	N/A	91.49%	16 Years
SAN Banco Santander	$0.18	1.89%	N/A	20.00%	N/A
SNY Sanofi	$1.60	3.44%	N/A	38.46%	N/A
SNYNF Sanofi	$2.80	3.03%	N/A	90.78%	N/A

Latest PFE, SNY, SNYNF, SAN, and MDCO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDCO Medicines	21.45	0.77	0.77
PFE Pfizer	0.65	1.16	0.85
SAN Banco Santander	N/A	0.26	0.26
SNY Sanofi	0.19	1.27	0.94
SNYNF Sanofi	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDCO Medicines	N/A
PFE Pfizer	68.36%
SAN Banco Santander	9.19%
SNY Sanofi	14.04%
SNYNF Sanofi	30.06%

Insider Ownership

Company	Insider Ownership
MDCO Medicines	8.41%
PFE Pfizer	0.06%
SAN Banco Santander	9.48%
SNY Sanofi	1.00%
SNYNF Sanofi	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDCO Medicines	62	79.72 million	N/A	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
SAN Banco Santander	199,958	14.89 billion	13.47 billion	Optionable
SNY Sanofi	82,878	2.46 billion	2.43 billion	Optionable
SNYNF Sanofi	91,600	N/A	N/A	Not Optionable

PFE, SNY, SNYNF, SAN, and MDCO Headlines

Recent News About These Companies

Sanofi falls after late-stage trial data for eczema therapy

September 4 at 4:21 PM | msn.com

Sanofi Drops As Eczema Drug Faces Big Test

September 4 at 4:21 PM | finance.yahoo.com

Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

September 4 at 2:45 AM | finance.yahoo.com

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

August 30, 2025 | finance.yahoo.com

Sanofi (ENXTPA:SAN): Revisiting Valuation as Shares Rebound After Volatile Period

August 22, 2025 | finance.yahoo.com

Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)

August 13, 2025 | theglobeandmail.com

Sanofi halts Praluent supply in China due to limited availability

August 12, 2025 | finance.yahoo.com

Sanofi’s New Study Aims for Early Detection of Type 1 Diabetes in At-risk Youth

August 9, 2025 | theglobeandmail.com

Sanofi (SNYNF) was upgraded to a Buy Rating at J.P. Morgan

August 9, 2025 | theglobeandmail.com

Europe markets mixed as earnings, tariff uncertainty dominate market sentiment

August 6, 2025 | msn.com

DZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)

August 3, 2025 | theglobeandmail.com

Sanofi outlines high single-digit sales growth for 2025 while advancing innovation pipeline and strategic acquisitions

July 31, 2025 | msn.com

Press release: Online availability of Sanofi’s half-year financial report for 2025

July 31, 2025 | finance.yahoo.com

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

July 31, 2025 | finance.yahoo.com

Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

July 30, 2025 | uk.finance.yahoo.com

Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis

July 30, 2025 | msn.com

Deutsche Bank Sticks to Its Hold Rating for Sanofi (SNYNF)

July 24, 2025 | theglobeandmail.com

Press Release: Sanofi announces extension of Blueprint tender offer

July 17, 2025 | finance.yahoo.com

Kepler Capital Remains a Hold on Sanofi (SNYNF)

July 13, 2025 | theglobeandmail.com

FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart

July 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, SNY, SNYNF, SAN, and MDCO Company Descriptions

Medicines NASDAQ:MDCO

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Pfizer NYSE:PFE

$24.86 +0.32 (+1.28%)

Closing price 03:59 PM Eastern

Extended Trading

$24.85 0.00 (-0.02%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Banco Santander NYSE:SAN

$9.52 -0.06 (-0.57%)

Closing price 03:59 PM Eastern

Extended Trading

$9.49 -0.04 (-0.37%)

As of 08:00 PM Eastern

Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.

Sanofi NASDAQ:SNY

$46.50 +1.17 (+2.58%)

Closing price 04:00 PM Eastern

Extended Trading

$46.60 +0.09 (+0.20%)

As of 07:44 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi OTCMKTS:SNYNF

$92.30 +0.49 (+0.54%)

As of 02:56 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, SNY, SNYNF, SAN, and MDCO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, SNY, SNYNF, SAN, and MDCO Earnings

Compare Dividends

Latest PFE, SNY, SNYNF, SAN, and MDCO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, SNY, SNYNF, SAN, and MDCO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, SNY, SNYNF, SAN, and MDCO Company Descriptions

Medicines NASDAQ:MDCO

Pfizer NYSE:PFE

Banco Santander NYSE:SAN

Sanofi NASDAQ:SNY

Sanofi OTCMKTS:SNYNF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools